NANS

Across TCGA pan-cancer cohorts, NANS mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NANS data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NANS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NANS expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and GBM are the cancer types where NANS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	1.000	0.449	.023	10	view →
PDAC	DFS	Quartile	All	0.889	0.670	.022	8	view →
GBM	OS	Quartile	All	0.261	0.550	.013	7	view →
CCRCC	DFS	Median	III,IV	0.441	0.743	.019	4	view →
LSCC	OS	Quartile	II,III,IV	0.684	0.926	.032	2	view →
LUAD	OS	Quartile	II,III,IV	0.839	0.268	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NANS–HNSC (OS)

Open the HNSC breakdown →